Table 1.
Pretreatment and treatment patient and disease features for the whole study cohort and per Pan-Immune-Inflammation-Value groups.
| Variables | All patients (N = 89) | PIV < 417 (N = 36) | PIV ≥4 17 (N = 53) | p-value |
|---|---|---|---|---|
| Median age, years | 61 (37–79) | 63 (41–78) | 60 (37–79) | 0.62 |
| Age, n (%) | ||||
| <70 | 74 (83,1) | 33 (91.7) | 41 (77.4) | 0.091 |
| ≥70 | 15 (16.9) | 3 (8.3) | 12 (22.6) | |
| Gender, n (%) | ||||
| Male | 75 (84.3) | 29 (80.6) | 46 (86.8) | 0.56 |
| Female | 14 (15.7) | 7 (19.4) | 7 (13.2) | |
| ECOG, n (%) | ||||
| 0–1 | 70 (78.6) | 28 (77.8) | 42 (79.2) | 0.83 |
| 2 | 19 (21.4) | 8 (22.2) | 11 (20.8) | |
| Smoking status, n (%) | ||||
| Never smoked | 14 (15.7) | 6 (16.7) | 8 (15.1) | 0.78 |
| Ex-smoker | 75 (96.0) | 30 (83.3) | 45 (84.9) | |
| T-stage, n (%) | ||||
| 1–2 | 38 (42.7) | 17 (47.2) | 21 (39.6) | 0.32 |
| 3–4 | 51 (57.3) | 19 (52.8) | 32 (60.4) | |
| N-stage, n (%) | ||||
| 1 | 22 (24.7) | 10 (27.8) | 12 (22.6) | 0.39 |
| 2–3 | 67 (75.3) | 26 (72.2) | 41 (77.4) | |
| TNM stage, n (%) | ||||
| II | 20 (22.5) | 9 (25.0) | 11 (20.8) | 0.46 |
| III | 69 (77.5) | 27 (75.0) | 42 (79.2) | |
| Mean pretreatment blood parameters, 103 per μL | ||||
| Monocytes | 0.44 (0.21–1.17) | 0.27 (0.22–0.64) | 0.56 (0.21–1.17) | <0.001 |
| Neutrophils | 4.13.0 (2.17–9.37) | 3.11 (2.17–6.48) | 5.89 (3.68–9.37) | 0.001 |
| Platelets | 276 (155–549) | 198 (155–336) | 297 (197–549) | 0.003 |
| Lymphocytes | 3.26 (1.71–5.13) | 4.28 (2.67–5.13) | 2.07 (1.71–5.13) | <0.001 |
| Anemia, n (%) | ||||
| Absent | 39 (43.8) | 19 (52,8) | 20 (37.7) | 0.19 |
| Present | 50 (56.2) | 17 (47,2) | 33 (62.3) | |
| Total chemotherapy cycles, n (%) | ||||
| 3 | 13 (14.6) | 5 (13.9) | 8 (15.1) | 0.73 |
| 4 | 76 (85.4) | 31 (86.1) | 45 (84.9) | |
PIV: pan-immune-inflammation value; ECOG: eastern cooperative oncology group; T-stage: tumor stage, N-stage: nodal stage; TNM: tumor-node-metastasis.